Iceland· IS-EU/1/10/643/001
Rapiscan
A regadenoson product containing regadenosonum inn, registered in Iceland by GE Healthcare AS. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Regadenoson is registered in 13 of 19 countries.
Countries holding a registration under ATC C01EB21 (regadenoson), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Regadenoson · ATC C01EB21
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Regadenosonum INN
- Manufacturer
- GE Healthcare AS
- Country
- Iceland (IS)
- ATC code
- C01EB21
- ATC class
- Regadenoson
- Defined daily dose
- 0.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean9901365 ml x1 hglISK 19746
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for regadenoson.
Graded by severity as the source publishes them — 6 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Regadenoson · interactions on record
6 records
- 6 moderate
Most severe, free to view
- DipyridamoleB01AC07moderate
- DipyridamolC01DX29moderate
- TheophyllinC01EB28moderate
- CaffeineN06BC01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Regadenoson in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLEXISCANAstellas Pharma US, Inc.
- FinlandRapiscanGE Healthcare AS
- CzechiaRAPISCANGE Healthcare AS, Oslo
- SpainRapiscan 400mcg solucion inyectableGe Healthcare As
- FranceRAPISCAN 400 microgrammes, solution injectableGE HEALTHCARE (NORVEGE)
- BelgiumRapiscan 400 µgGE Healthcare
- IrelandRapiscan 400 microgram solution for injectionGE Healthcare AS
- NetherlandsRapiscan 400 microgram oplossing voor injectieGE Healthcare AS
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Rapiscan
- Liechtenstein · Rapiscan
- Norway · Rapiscan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/06acdea9-a9e8-4c4f-b391-63e4d31eaf2c GET /v1/drugs/06acdea9-a9e8-4c4f-b391-63e4d31eaf2c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "C01EB21",
"marketed": false,
"strength": "400 míkróg",
"ma_number": "EU/1/10/643/001",
"substance": "Regadenosonum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "40477"
}See everything about regadenoson.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.